The American Journal of Managed Care

Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy ...
The American Journal of Managed Care

BTK Inhibitors in R/R CLL: Navigating Options and Tailoring Treatment

Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite ...
Targeted Oncology

The Paradox of Progress: Personalizing First-Line Therapy in CLL

Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...
Targeted Oncology

Navigating the Future of CLL Care

The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on ...
Medscape

Mutations in Half of Patients With CLL Who Relapse on Ibrutinib

STOCKHOLM — Approximately half of patients with chronic lymphocytic leukemia (CLL) who relapse after treatment with ibrutinib (Imbruvica, Pharmacyclics) show acquired mutations in the Bruton's ...
Nasdaq

Nurix Therapeutics Showcases Promising Preclinical Data for BTK, BRAF, and Aurora A Kinase Degraders at AACR 2025 Annual Meeting

Nurix Therapeutics, Inc. presented promising preclinical data at the AACR 2025 Annual Meeting, showcasing their innovative targeted protein degradation medicines aimed at addressing various cancers, ...
Morningstar

The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that ...

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288

Ascentage Pharma will be conducting a multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in ...
Nasdaq

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell ...

Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a rapid and sustained complete response; Phase 1b expansion cohort also initiated ...
Seeking Alpha

Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025

DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with ORR of 84.2% DZD6008, a BBB-penetrant 4 th ...
KTLA

The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an ...